Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference
Cidara Therapeutics (CDTX) has announced its participation in the Evercore 7th Annual HealthCONx Conference. The company's President and CEO, Jeffrey Stein, Ph.D., will engage in a fireside chat on Tuesday, December 3, 2024, at 7:55 AM ET. The presentation will be available via webcast, with a 90-day replay accessible in the Investors section of Cidara's website. The company, which develops drug-Fc conjugate immunotherapies through its proprietary Cloudbreak® platform, will also conduct one-on-one investor meetings during the event.
Cidara Therapeutics (CDTX) ha annunciato la sua partecipazione alla 7ª Conferenza Annuale HealthCONx di Evercore. Il Presidente e CEO dell'azienda, Jeffrey Stein, Ph.D., parteciperà a un dibattito informale martedì 3 dicembre 2024, alle 7:55 AM ET. La presentazione sarà disponibile in diretta streaming, con una registrazione accessibile per 90 giorni nella sezione Investitori del sito web di Cidara. L'azienda, che sviluppa terapie immunologiche coniugate a farmaci tramite la propria piattaforma proprietaria Cloudbreak®, condurrà anche incontri individuali con gli investitori durante l'evento.
Cidara Therapeutics (CDTX) ha anunciado su participación en la 7ª Conferencia Anual HealthCONx de Evercore. El Presidente y CEO de la compañía, Jeffrey Stein, Ph.D., participará en una charla informal el martes 3 de diciembre de 2024, a las 7:55 AM ET. La presentación estará disponible a través de una transmisión web, con una grabación accesible durante 90 días en la sección de Inversores del sitio web de Cidara. La empresa, que desarrolla inmunoterapias conyugadas a fármacos a través de su plataforma propietaria Cloudbreak®, también llevará a cabo reuniones individuales con los inversores durante el evento.
시다라 제약(CDTX)가 에버코어 제7회 연례 헬스콘x 컨퍼런스에 참여한다고 발표했습니다. 회사의 회장 겸 CEO인 제프리 스타인 박사(Jeffrey Stein, Ph.D.)는 2024년 12월 3일 화요일 오전 7시 55분(ET)에 공개 대화에 참석할 예정입니다. 발표는 웹 캐스트를 통해 제공되며, Cidara 웹사이트의 투자자 섹션에서 90일 동안 재생할 수 있습니다. 약물-Fc 접합 면역요법을 개발하는 이 회사는 행사 기간 동안 개별 투자자 회의도 진행할 것입니다.
Cidara Therapeutics (CDTX) a annoncé sa participation à la 7ème Conférence Annuelle HealthCONx d'Evercore. Le Président et CEO de l'entreprise, Jeffrey Stein, Ph.D., participera à une discussion informelle mardi 3 décembre 2024, à 7h55 ET. La présentation sera disponible par webdiffusion, avec un replay accessible pendant 90 jours dans la section Investisseurs du site de Cidara. L'entreprise, qui développe des immunothérapies conjuquées à des médicaments via sa plateforme propriétaire Cloudbreak®, tiendra également des réunions individuelles avec les investisseurs durant l'événement.
Cidara Therapeutics (CDTX) hat seine Teilnahme an der 7. jährlichen HealthCONx-Konferenz von Evercore bekannt gegeben. Der Präsident und CEO des Unternehmens, Jeffrey Stein, Ph.D., wird am Dienstag, dem 3. Dezember 2024, um 7:55 Uhr ET an einem informellen Gespräch teilnehmen. Die Präsentation wird als Webcast verfügbar sein, mit einer 90-tägigen Wiederholung, die im Investor-Bereich der Cidara-Website zugänglich ist. Das Unternehmen, das Arzneimittel-Fc-Konjugat-Immuntherapien über seine proprietäre Cloudbreak®-Plattform entwickelt, wird während der Veranstaltung auch Einzelgespräche mit Investoren führen.
- None.
- None.
SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Evercore 7th Annual HealthCONx Conference.
Details are as follows:
Event: Evercore 7th Annual HealthCONx Conference
Date: Tuesday, December 3, 2024
Time: 7:55 AM ET
Format: Fireside chat
Webcast: https://wsw.com/webcast/evercore44/cdtx/2373273
A replay of the presentation will be available in the Investors section on the Company’s website at www.cidara.com. The replay of the presentation will be available for 90 days.
Cidara will also participate in one-on-one investor meetings during this event. Investors interested in meeting with Cidara at the conference should contact their Evercore representative directly.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced initiation of a Phase 2b trial in September 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When is Cidara Therapeutics (CDTX) presenting at the Evercore HealthCONx Conference 2024?
How can I watch Cidara Therapeutics' (CDTX) presentation at the Evercore Conference?
What type of presentation will Cidara Therapeutics (CDTX) give at the Evercore Conference?
How long will Cidara Therapeutics' (CDTX) Evercore Conference presentation replay be available?
